John Hubbard

John Hubbard, Ph.D., FCP, is a member of Genstar’s Strategic Advisory Board, advising the firm in the area of healthcare.

John has more than 34 years of leadership experience in the biopharmaceutical and pharma services industries. He was the President and Chief Executive Officer of Bioclinica, a leading provider of medical imaging, clinical technologies and development services. Over three years, Bioclinica doubled in size, completed four acquisitions and expanded its customer base to more than 400 corporations, including the top 100 biopharmaceutical companies and top ten CROs. Bioclinica was sold to a global Private Equity firm and John retired as CEO in January 2018.

Prior to Bioclinica, John was Senior Vice President and Worldwide Head of Development Operations at Pfizer, where he directed and led global clinical operations and development. He was a member of the Portfolio Strategy and Investment Committee, Co-Chair of the Clinical and Medical Excellence Innovation Board, Co-Chair of the early Development Committee, and also served on the executive taskforce that redesigned Pfizer’s R&D organization. John was a founding member of the Board of Directors of TransCelerate Biopharma, Inc., a leading biopharma industry consortium, and served on the Executive, Audit and Finance Committees.

Before joining Pfizer, he was Group President of ICON plc’s Global Clinical Research Services Division, the company’s largest business unit generating over $750 million in revenues in 2010. During John’s tenure, ICON was named one of the country’s fastest growing companies by FORTUNE and achieved record growth from $85 million in annual revenues in 1999 to over $900 million in revenues in 2010, becoming one of the top “5” global CROs.

John has also held executive positions at Parexel International Corporation and Sanofi Pharmaceuticals (formerly Hoechst Marion Roussel Pharmaceuticals). He is currently Chairman of the Signant Health Board and a Board Member of Advarra, two of Genstar’s portfolio companies, and also on Science 37 and Agile Therapeutics (NASDAQ: AGRX) Board of Directors. He is an Executive Committee Member Emeritus on the Clinical Trials Transformation Initiative, Board Member of Life Sciences PA and former Chairman of the Board of the Association of Clinical Research Organizations (ACRO).